Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.48 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.44 |
| ▸ | PLAU | P00749 | 3/20 | 0.42 |
| ▸ | PLAUR | Q03405 | 3/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16800548 | 0.88 | GSR (0.44) | GSRRNPEPCPB2PLAUPLAUR | |
| SCHEMBL8387444 | 0.86 | GSR (0.42) | GSRRNPEPCPB2PLAUPLAUR | |
| SCHEMBL1673011 | 0.83 | SLC6A9 (0.40) | GSRRNPEPCPB2PLAUPLAUR | |
| SCHEMBL410472 | 0.83 | SLC6A9 (0.40) | GSRRNPEPCPB2PLAUPLAUR | |
| SCHEMBL2240651 | 0.81 | SLC6A9 (0.39) | GSRRNPEPCPB2PLAUPLAUR | |
| SCHEMBL18120975 | 0.78 | MMP2 (0.50) | GSRDPP7DPP4DPP8DPP9 | |
| SCHEMBL10088097 | 0.76 | LMNA (0.38) | CPB2PLAUPLAURDPP7 | |
| SCHEMBL30973670 | 0.75 | ALB (0.39) | GSRFOLH1CYP2D6NFKB1 | |
| SCHEMBL23504921 | 0.74 | SLC6A9 (0.42) | GSR | |
| SCHEMBL1696968 | 0.74 | GSR (0.44) | GSRRNPEPCPB2DPP7DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173442-A1 | COMBINATION THERAPY | HOFFMANN-LA ROCHE INC. | 2024-05-30 | — | — | US | disclosed |
| EP-3781200-B1 | ANTIBODIES FOR CHELATED RADIONUCLIDES | HOFFMANN LA ROCHE (CH) | 2024-05-29 | — | — | EP | disclosed |
| US-20240082437-A1 | SPLIT ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS | HOFFMANN-LA ROCHE INC. (US) | 2024-03-14 | — | — | US | disclosed |
| EP-4277668-A1 | COMBINATION THERAPY | F. Hoffmann-La Roche AG (CH) | 2023-11-22 | — | — | EP | disclosed |
| EP-4277705-A1 | SPLIT ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS | F. Hoffmann-La Roche AG (CH) | 2023-11-22 | — | — | EP | disclosed |
| CN-116829593-A | Dividing antibodies that bind to cancer cells and target radionuclides to said cells | 豪夫迈·罗氏有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-116744981-A | combination therapy | 豪夫迈·罗氏有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230272116-A1 | ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS | HOFFMANN-LA ROCHE INC. | 2023-08-31 | — | — | US | disclosed |
| EP-4178985-A1 | ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS | F. Hoffmann-La Roche AG (CH) | 2023-05-17 | — | — | EP | disclosed |
| CN-115867583-A | Antibodies that bind to cancer cells and target radionuclides to said cells | 豪夫迈·罗氏有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20130071413-A1 | TARGETED IMMUNE CONJUGATES | AUGMENTA BIOLOGICALS, LLC (US) | 2013-03-21 | — | — | US | disclosed |
| EP-2563396-A2 | DELIVERY PROTEINS | Augmenta Biologicals LLC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-8318912-B2 | Targeted immune conjugate comprising an antibody to glycophorin A and a M2e peptide | AUGMENTA BIOLOGICALS, LLC (US) | 2012-11-27 | — | — | US | disclosed |
| WO-2012158195-A2 | TOXIN AND PATHOGEN CLEARANCE | AUGMENTA BIOLOGICALS, LLC (US) | 2012-11-22 | — | — | WO | disclosed |
| EP-2403530-A2 | ENGINEERED PROTEINS WITH HIGH AFFINITY FOR DOTA CHELATES | Massachusetts Institute of Technology (US) | 2012-01-11 | — | — | EP | disclosed |
| WO-2011137354-A2 | DELIVERY PROTEINS | AUGMENTA BIOLOGICALS, LLC (US) | 2011-11-03 | — | — | WO | disclosed |
| US-20100254987-A1 | ENGINEERED PROTEINS WITH HIGH AFFINITY FOR DOTA CHELATES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-10-07 | — | — | US | disclosed |
| WO-2010099536-A2 | ENGINEERED PROTEINS WITH HIGH AFFINITY FOR DOTA CHELATES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010062502-A1 | CARRIERS FOR THE DELIVERY OF NUCLEIC ACIDS TO CELLS AND METHODS OF USE THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20100003266-A1 | TARGETED IMMUNE CONJUGATES | AUGMENTA BIOLOGICALS, LLC | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173442-A1 | COMBINATION THERAPY | CD47, PAICS, CD22 | GSR 4208/4885RNPEP 554/4885CPB2 1470/4885 |
| US-20230272116-A1 | ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS | CD47, FCGR3B, CD2 | GSR 4253/4885RNPEP 506/4885CPB2 2622/4885 |
| US-20240082437-A1 | SPLIT ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS | CD47, CD2, CD4 | GSR 4198/4885RNPEP 212/4885CPB2 616/4885 |
| US-20100254987-A1 | ENGINEERED PROTEINS WITH HIGH AFFINITY FOR DOTA CHELATES | TFRC, STAMBP, MAX | GSR 4284/4885RNPEP 94/4885CPB2 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.